Medtronic (MDT) FY2026 10-K Annual Report
Medtronic (MDT) 10-K annual report for fiscal year 2026, filed with SEC EDGAR on Jun 18, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Medtronic FY2026 10-K Analysis
Business Overview
- • Core business model: Global healthcare technology company developing, manufacturing, and selling device-based medical therapies and services across Cardiovascular, Neuroscience, and Medical Surgical segments
- • New strategic emphasis: Separation and IPO of Diabetes Business into independent public company MiniMed Group in March 2026
- • Strategic shift: Focus on AI, data analytics, and automation to tailor therapies and enable remote monitoring care delivery
- • Notable quantitative metric: Over 95,000 full-time employees globally, with 43% based in U.S. or Puerto Rico; achieved 100% U.S. pay equity by gender and ethnicity
- • Unique fact in 2026 filing: Diabetes segment is no longer reportable post-MiniMed IPO, affecting segment comparability in future financial metrics
Management Discussion & Analysis
- • Revenue $36.4B, up 8.4% YoY from $33.5B driven by growth across Cardiovascular (+12% to $14.0B), Neuroscience (+4% to $10.3B), Medical Surgical (+5% to $8.8B), and Diabetes (+13% to $3.1B)
- • Operating margin info not explicitly given; cost of products sold margin increased with COGS $12.7B vs $11.6B, SG&A increased $11.8B vs $10.8B, R&D increased $2.9B vs $2.7B; effective tax rate 21.2% vs 16.6%, non-GAAP nominal tax 17.3% vs 16.7%
- • Best performing segment: Cardiovascular, net sales $13.98B, +12% YoY; Worst performing segment by growth: Specialty Therapies, +2% to $3.0B
- • Free cash flow $5.43B vs $5.19B; capital allocation included share repurchases 10M shares ($932.5M avg price), dividends (not quantified), $1.9B capex; $3.3B net increase in debt issuance/repayments, IPO proceeds $538M from MiniMed
- • Forward outlook risks: $250M estimated tariffs in FY27, geopolitical risks (Russia-Ukraine, Middle East conflicts), impact of Diabetes separation, regulatory/commercial challenges; growth expected in cardiovascular device adoption and new product launches, Neuroscience AI-assisted surgery growth, Medical Surgical robotics expansion
Risk Factors
- • EU Medical Device Regulation (EU MDR) implementation extended to 2028, imposing additional pre- and post-market requirements and severe penalties for non-compliance
- • Russia-Ukraine conflict causing supply chain risks from materials like palladium and neon; Russia and Belarus sanctions disrupt regional business activities
- • Sole-source sterilization facilities with limited capacity create risk of manufacturing delays or lost sales if facilities are damaged or closed
- • Competition from pharmaceutical companies producing GLP-1s and emerging AI-enabled digital health tools may disrupt market share and product adoption
- • Ongoing U.S. tax litigation over income allocation to Puerto Rico manufacturing site with appellate remand in 2025 could materially impact financial condition
Medtronic FY2026 Key Financial MetricsXBRL
Revenue
$36.4B
▲ +8.4% YoY
Net Income
$4.8B
▲ +3.0% YoY
Operating Margin
17.8%
▲ +3bp YoY
Net Margin
13.2%
▼ -70bp YoY
ROE
9.7%
▼ -0bp YoY
Total Assets
$93.0B
▲ +1.5% YoY
EPS (Diluted)
$3.73
▲ +3.3% YoY
Operating Cash Flow
$7.3B
▲ +4.1% YoY
Source: XBRL data from Medtronic FY2026 10-K filing on SEC EDGAR. All figures in USD.
Other Medtronic Annual Reports
Get deeper insights on Medtronic
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.